0001641172-25-006669.txt : 20250429 0001641172-25-006669.hdr.sgml : 20250429 20250429164509 ACCESSION NUMBER: 0001641172-25-006669 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ocean Biomedical, Inc. CENTRAL INDEX KEY: 0001869974 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 871309280 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40793 FILM NUMBER: 25888616 BUSINESS ADDRESS: STREET 1: 515 MADISON AVE SUITE 8078 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 908-2658 MAIL ADDRESS: STREET 1: 515 MADISON AVE SUITE 8078 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: Ocean Biomedical, Inc./DE DATE OF NAME CHANGE: 20230214 FORMER COMPANY: FORMER CONFORMED NAME: Aesther Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20210628 10-K/A 1 form10-ka.htm ANNUAL REPORT
true FY 0001869974 0001869974 2024-01-01 2024-12-31 0001869974 OCEA:CommonStockParValue0.0001PerShareMember 2024-01-01 2024-12-31 0001869974 OCEA:WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2024-01-01 2024-12-31 0001869974 2024-06-30 0001869974 2025-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

AMENDMENT NO. 1 TO FORM 10-K

 

FORM 10-K/A

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2024

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to _____

 

Commission File Number: 001-40793

 

Ocean Biomedical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   87-1309280

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification Number)

 

55 Claverick St., Room 325

Providence, RI

   02903
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (401) 444-7375

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   OCEA   The NASDAQ Stock Market LLC
Warrants, each exercisable for one share of common stock at an exercise price of $11.50   OCEAW   The NASDAQ Stock Market LLC

 

Securities registered pursuant to section 12(g) of the Act: None.

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☒ Smaller reporting company ☒
       
Emerging growth company ☒    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s voting and non-voting common stock held by non-affiliates of the registrant on June 30, 2024, based on the closing price of $1.22 for shares of the registrant’s common stock as reported by The Nasdaq Stock Market, was approximately $5,473,915.52.

 

There were 166,010,805 common stock shares of the registrant outstanding on March 31, 2025.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Definitive Schedule 14A filed with the SEC on February 26, 2025.

 

 

 

 

 

 

EXPLANATORY NOTE

 

Ocean Biomedical, Inc. (“Ocean Biomedical” or the “Company”) is filing this Amendment No. 1 to Form 10-K (this “Amendment”) to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Original Filing”), filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2025. The purpose of this Amendment is solely to disclose the information required in Part III (Items 10, 11, 12, 13 and 14) of the Original Filing, which information was previously omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Items 10 through 14 of Part III of the Original Filing are hereby amended and restated in their entirety by incorporation by reference from the Company’s Definitive Schedule 14A filed with the SEC on February 26, 2025. In addition, pursuant to Rule 12b-15 under the Exchange Act, the Company is including Item 15 of Part IV of this Amendment, solely to file the certifications required under Section 302 of the Sarbanes-Oxley Act of 2002. Except as described above, this Amendment does not amend any other information set forth in the Original Filing, and we have not updated disclosures included therein to reflect any subsequent events.

 

2

 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Information about directors, executive officers and corporate governance is presented under the same captions in our definitive Proxy Statement on Schedule 14A filed with the SEC on February 26, 2025 (the “Proxy Statement”) and is incorporated herein by reference.

 

Insider Trading Policy

 

We maintain, and periodically review, an insider trading policy that governs the purchase, sale and/or disposition of our securities by our directors, officers, employees and contractors who may have access to and/or possession of material non-public information. We have implemented processes that we believe are reasonably designed to promote compliance by us and by the covered persons with insider trading laws, rules and regulations and applicable listing standards. A copy of our Insider Trading Policy is filed as Exhibit 19.1 to this Annual Report.

 

ITEM 11. EXECUTIVE COMPENSATION

 

Information about executive compensation is presented under the same captions in our definitive Proxy Statement in the Proxy Statement and is incorporated herein by reference.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Information about security ownership of certain beneficial owners and management and related stockholder matters is presented under the same captions in the Proxy Statement and is incorporated herein by reference.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

Information about certain relationships and related transactions, and director independence is presented under the same captions in the Proxy Statement and in the Company’s Annual Report on Form 10-K filed with the SEC on April 8, 2025 and is incorporated by reference.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

 

Information about principal accountant fees and services is presented under the same captions in the Proxy Statement and is incorporated herein by reference.

 

3

 

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES.

 

Exhibit No.   Description
     
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act.
     
31.2*   Certification of Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act.

 

101.INS   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.
   
** Furnished herewith.
   
† Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon request; provided, however, that the Registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act, as amended, for any schedule or exhibit so furnished.
   
# Represents management compensation plan, contract or arrangement.
   
+ As permitted by Regulation S-K, Item 601(b)(10)(iv) of the Securities Exchange Act of 1934, as amended, certain confidential portions of this exhibit have been redacted from the publicly filed document. The Registrant agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request.

 

Item 16. Form 10-K Summary.

 

Not applicable.

 

4

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

April 29, 2025 Ocean Biomedical, Inc.
   
  By: /s/ Chirinjeev Kathuria
  Name: Chirinjeev Kathuria
  Title: Chairman of the Board
    (Principal Executive Officer)

 

5

 

 EX-31.1 2 ex31-1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

 

Exhibit 31.1

 

Certification of Principal Executive Officer

 

I, Chirinjeev Kathuria, certify that:

 

1. I have reviewed this Annual Report on Form 10-K/A of Ocean Biomedical, Inc. (the “registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 29, 2025  
   
/s/ Chirinjeev Kathuria  
Chirinjeev Kathuria  
Chairman of the Board (Principal Executive Officer)  

 

 

 

 EX-31.2 3 ex31-2.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER

 

Exhibit 31.2

 

Certification of Chief Financial Officer

 

I, Jolie Kahn, certify that:

 

1. I have reviewed this Annual Report on Form 10-K/A of Ocean Biomedical, Inc. (the “registrant”);
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 29, 2025  
   
/s/ Jolie Kahn  
Jolie Kahn  
Chief Financial Officer (Principal Accounting/Financial Officer)  

 

 

 

 EX-101.SCH 4 ocea-20241231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 ocea-20241231_def.xml XBRL DEFINITION FILE EX-101.LAB 6 ocea-20241231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common stock, par value $0.0001 per share Warrants, each exercisable for one share of common stock at an exercise price of $11.50 Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Type [Axis] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Trading Arrangements, by Individual [Table] Trading Arrangement [Axis] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name EX-101.PRE 7 ocea-20241231_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 31, 2025
Jun. 30, 2024
Document Type 10-K/A    
Amendment Flag true    
Amendment Description Ocean Biomedical, Inc. (“Ocean Biomedical” or the “Company”) is filing this Amendment No. 1 to Form 10-K (this “Amendment”) to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Original Filing”), filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2025. The purpose of this Amendment is solely to disclose the information required in Part III (Items 10, 11, 12, 13 and 14) of the Original Filing, which information was previously omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Items 10 through 14 of Part III of the Original Filing are hereby amended and restated in their entirety by incorporation by reference from the Company’s Definitive Schedule 14A filed with the SEC on February 26, 2025. In addition, pursuant to Rule 12b-15 under the Exchange Act, the Company is including Item 15 of Part IV of this Amendment, solely to file the certifications required under Section 302 of the Sarbanes-Oxley Act of 2002. Except as described above, this Amendment does not amend any other information set forth in the Original Filing, and we have not updated disclosures included therein to reflect any subsequent events.    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-40793    
Entity Registrant Name Ocean Biomedical, Inc.    
Entity Central Index Key 0001869974    
Entity Tax Identification Number 87-1309280    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 55 Claverick St.    
Entity Address, Address Line Two Room 325    
Entity Address, City or Town Providence    
Entity Address, State or Province RI    
Entity Address, Postal Zip Code 02903    
City Area Code (401)    
Local Phone Number 444-7375    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status No    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 5,473,915.52
Entity Common Stock, Shares Outstanding   166,010,805  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Common stock, par value $0.0001 per share      
Title of 12(b) Security Common stock, par value $0.0001 per share    
Trading Symbol OCEA    
Security Exchange Name NASDAQ    
Warrants, each exercisable for one share of common stock at an exercise price of $11.50      
Title of 12(b) Security Warrants, each exercisable for one share of common stock at an exercise price of $11.50    
Trading Symbol OCEAW    
Security Exchange Name NASDAQ    
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 5 38 1 false 2 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://oceanbiomedical.com/role/Cover Cover Cover 1 false false R2.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 2 false false All Reports Book All Reports form10-ka.htm ocea-20241231.xsd ocea-20241231_def.xml ocea-20241231_lab.xml ocea-20241231_pre.xml http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-ka.htm": { "nsprefix": "OCEA", "nsuri": "http://oceanbiomedical.com/20241231", "dts": { "inline": { "local": [ "form10-ka.htm" ] }, "schema": { "local": [ "ocea-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "ocea-20241231_def.xml" ] }, "labelLink": { "local": [ "ocea-20241231_lab.xml" ] }, "presentationLink": { "local": [ "ocea-20241231_pre.xml" ] } }, "keyStandard": 38, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 5, "entityCount": 1, "segmentCount": 2, "elementCount": 156, "unitCount": 4, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 40, "http://xbrl.sec.gov/ecd/2024": 1 }, "report": { "R1": { "role": "http://oceanbiomedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "2", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-ka.htm", "first": true, "unique": true } } }, "tag": { "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r47" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r53" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r53" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r53" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r53" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r18", "r29", "r39", "r65" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r21", "r32", "r42", "r68" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r53" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r60" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r22", "r33", "r43", "r60", "r69", "r73", "r81" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "auth_ref": [ "r79" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r25" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r25" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r76" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r77" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r72" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r72" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r72" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r72" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r72" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r72" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r75" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r74" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r73" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r73" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r51" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r52" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r52" ] }, "OCEA_CommonStockParValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://oceanbiomedical.com/20241231", "localname": "CommonStockParValue0.0001PerShareMember", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common stock, par value $0.0001 per share" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r57" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r56" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r58" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r55" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r25" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r11", "r13", "r25", "r61" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r46" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r88" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r85" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r25" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r86" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r54" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r18", "r29", "r39", "r65" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r15", "r26", "r36", "r62" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r60" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r22", "r33", "r43", "r69" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r22", "r33", "r43", "r69" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r22", "r33", "r43", "r69" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r22", "r33", "r43", "r69" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r22", "r33", "r43", "r69" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r11", "r13", "r25" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r22", "r33", "r43", "r60", "r69", "r73", "r81" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r79" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r14", "r84" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r14", "r84" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r14", "r84" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r52" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r52" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r72" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r80" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r53" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r52" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r50" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r49" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r80" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r80" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r52" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r20", "r31", "r41", "r67" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r23", "r34", "r44", "r70" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r23", "r34", "r44", "r70" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r48" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r51" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r51" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r50" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r53" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r49" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r50" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r48" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r48" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r15", "r26", "r36", "r62" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r16", "r27", "r37", "r63" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r17", "r28", "r38", "r64" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r24", "r35", "r45", "r71" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r80" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r80" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r19", "r30", "r40", "r66" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r59" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r51" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r58" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r79" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r81" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r82" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r83" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r83" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r81" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r81" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r82" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r78" ] }, "OCEA_WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member": { "xbrltype": "domainItemType", "nsuri": "http://oceanbiomedical.com/20241231", "localname": "WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants, each exercisable for one share of common stock at an exercise price of $11.50" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://oceanbiomedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r87" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r21": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r22": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r23": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r24": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r25": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r26": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r27": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r28": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r29": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r30": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r31": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r32": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r33": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r34": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r35": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r36": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r37": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r38": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r39": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r40": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r41": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r42": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r43": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r44": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r45": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r46": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r47": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r48": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r49": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r50": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r51": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r52": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r53": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r54": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r55": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r56": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r57": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r58": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r59": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r60": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r61": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r62": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r63": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r64": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r65": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r66": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r67": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r68": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r69": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r70": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r71": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r72": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r73": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r74": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r75": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r76": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r77": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r78": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r79": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r80": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r81": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r82": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r83": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r84": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r85": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r86": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r87": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r88": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001641172-25-006669-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641172-25-006669-xbrl.zip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ԟ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end XML 19 form10-ka_htm.xml IDEA: XBRL DOCUMENT 0001869974 2024-01-01 2024-12-31 0001869974 OCEA:CommonStockParValue0.0001PerShareMember 2024-01-01 2024-12-31 0001869974 OCEA:WarrantsEachExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2024-01-01 2024-12-31 0001869974 2024-06-30 0001869974 2025-03-31 iso4217:USD shares iso4217:USD shares pure true FY 0001869974 10-K/A true 2024-12-31 --12-31 2024 false 001-40793 Ocean Biomedical, Inc. DE 87-1309280 55 Claverick St. Room 325 Providence RI 02903 (401) 444-7375 Common stock, par value $0.0001 per share OCEA NASDAQ Warrants, each exercisable for one share of common stock at an exercise price of $11.50 OCEAW NASDAQ No No No Yes Non-accelerated Filer true true false false false false 5473915.52 166010805 Ocean Biomedical, Inc. (“Ocean Biomedical” or the “Company”) is filing this Amendment No. 1 to Form 10-K (this “Amendment”) to amend our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Original Filing”), filed with the Securities and Exchange Commission (the “SEC”) on April 8, 2025. The purpose of this Amendment is solely to disclose the information required in Part III (Items 10, 11, 12, 13 and 14) of the Original Filing, which information was previously omitted from the Original Filing in reliance on General Instruction G(3) to Form 10-K. In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Items 10 through 14 of Part III of the Original Filing are hereby amended and restated in their entirety by incorporation by reference from the Company’s Definitive Schedule 14A filed with the SEC on February 26, 2025. In addition, pursuant to Rule 12b-15 under the Exchange Act, the Company is including Item 15 of Part IV of this Amendment, solely to file the certifications required under Section 302 of the Sarbanes-Oxley Act of 2002. Except as described above, this Amendment does not amend any other information set forth in the Original Filing, and we have not updated disclosures included therein to reflect any subsequent events. true